key: cord-0913437-5ex8eo3z
authors: Rannard, Steven P.; McDonald, Tom O.; Owen, Andrew
title: Chasing COVID‐19 chemotherapeutics without putting the cart before the horse
date: 2020-11-20
journal: Br J Clin Pharmacol
DOI: 10.1111/bcp.14575
sha: e4802fedb8da986dc81274cb22f07b47e59708d2
doc_id: 913437
cord_uid: 5ex8eo3z

nan

rigorously optimised for the treatment of specific indications. Route of administration, dosage, and schedules for existing therapies were optimised to provide adequate plasma/tissue pharmacokinetics and safety for their target disease or condition. These cannot be assumed to be optimal for COVID-19 but are often highly predictable from pre-existing data and clinical experience. For example, hydroxychloroquine and lopinavir/ritonavir recently failed to deliver benefits in RCTs for mild/moderate and severe disease, 1,2 but the clear disconnect between reported in vitro antiviral activity and known human pharmacokinetics after administration of approved doses was predictable. 3 Interpretation of laboratory-based antiviral activity assessments is complicated by current uncertainty regarding the appropriateness of the existing model systems. The majority of in vitro antiviral screening assays have utilised Vero cells, which were derived from the kidney of African Green Monkey in the 1970s, and the lack of clinical evidence for which to validate the exposure-response relationship in humans is problematic. Evidence is emerging that the anti-SARS-CoV-2 activity of drugs may be higher in cells derived from humans. However, the question of which cell types are most representative of in vivo performance is yet to be addressed, and all that can really be concluded from current knowledge is that the susceptibility of SARS-CoV-2 to antivirals is cell-type-dependent. The consequences of this in terms of the variety of cell types known to be infected and/or sustain productive infection in vivo is equally uncertain and further exacerbated by the lack of robustly validated animal models. However, repurposed drugs cannot be assumed to be active against SARS-CoV-2 at a dose that was optimised on the basis of potency for and accumulation at their initial therapeutic target, and candidate selection should take care not to over-or under-represent the impact of plasma and tissue protein binding. In recent months, several multi-national screening initiatives have been launched to tackle some of these issues. Andrew Owen https://orcid.org/0000-0002-9819-7651

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

Prioritisation of anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics

A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-COV-2) treatments

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Remdesivir for the treatment of Covid-19-preliminary report

Favipiravir versus arbidol for COVID-19: a randomized clinical trial

Model-informed drug repurposing: viral kinetic modelling to prioritize rational drug combinations for COVID-19

Coronavirus breakthrough: dexamethasone is first drug shown to save lives

Long-acting injectable atovaquone nanomedicines for malaria prophylaxis

Safety and tolerability of longacting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial

Urgent appeal from International Society for Aerosols in Medicine (ISAM) during COVID-19: clinical decision makers and governmental agencies should consider the inhaled route of administration: a statement from the ISAM Regulatory and Standardization Issues Networking Group